222631-10-9

Basic information

• Product Name: 5H-1,3-Dioxolo4,5-cpyrrole-5-carboxylic acid, 4-(1-cyano-2-hydroxyethenyl)-6-(1,1-dimethylethyl)dimethylsilyloxymethyltetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-
• Synonyms: 5H-1,3-Dioxolo4,5-cpyrrole-5-carboxylic acid, 4-(1-cyano-2-hydroxyethenyl)-6-(1,1-dimethylethyl)dimethylsilyloxymethyltetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-
• CAS NO: 222631-10-9
• Molecular Formula: C22H38 N2 O6 Si
• Molecular Weight: 454.63
• Mol File: 222631-10-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5H-1,3-Dioxolo4,5-cpyrrole-5-carboxylic acid, 4-(1-cyano-2-hydroxyethenyl)-6-(1,1-dimethylethyl)dimethylsilyloxymethyltetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-1,3-Dioxolo4,5-cpyrrole-5-carboxylic acid, 4-(1-cyano-2-hydroxyethenyl)-6-(1,1-dimethylethyl)dimethylsilyloxymethyltetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-(222631-10-9)
• EPA Substance Registry System: 5H-1,3-Dioxolo4,5-cpyrrole-5-carboxylic acid, 4-(1-cyano-2-hydroxyethenyl)-6-(1,1-dimethylethyl)dimethylsilyloxymethyltetrahydro-2,2-dimethyl-, 1,1-dimethylethyl ester, (3aS,4S,6R,6aR)-(222631-10-9)

Safety Data

• Hazardous Substances Data: 222631-10-9(Hazardous Substances Data)

Upstream product

• 89747-54-6 (3R,4R,5R)-4,5-dihydro-3,4-(O,O)-isopropylidene-5-mesyloxymethyl-2-(3H)-furanone 
• 30725-00-9 2,3-O-isopropylidene-D-ribonic-γ-lactone 
• 5336-08-3 D-Ribono-1,4-lactone 
• 532-20-7 D-Ribose 
• 607389-17-3 (3aR,4S,6aS)-4-((tert-butyldimethylsilyl)methyl)-2,2-dimethyl-4,6a-dihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole 5-oxide 
• 153172-31-7 (3aR,4R,6aS)-4-({[(tert-butyl)(dimethyl)silyl]oxy}methyl)tetrahydro-2,2-dimethyl-3aH-[1,3]dioxolo[4,5-c]pyrrole 
• 153172-30-6 1-amino-1,4-anhydro-N-benzyl-5-O-tertbutyldimethylsilyl-1-deoxy-2,3-O-isopropylidene-D-ribitol 
• 1044813-00-4 5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-L-lyxonic acid-1,4-lactone 
• 152006-17-2 2,3-O-isopropylidene-L-lyxono-1,4-lactone 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 222631-09-6 (3aR,4R,6S,6aS)-tert-butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-6-(cyanomethyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H)-carboxylate 
• 222631-08-5 2-((3aS,4S,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo [4,5-c]pyrrol-4-yl)acetonitrile 
• 1610426-21-5 2-((3aS,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-5-hydroxy-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrol-4-yl)acetonitrile 

Downstream Products

• 222631-12-1 1-benzyl 2-ethyl 3-amino-4-((3aS,4S,6R,6aR)-5-(tert-butoxycarbonyl)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo [4,5-c]pyrrol-4-yl)-1H-pyrrole-1,2-dicarboxylate 
• 284490-15-9 (3aS,4S,6R,6aR)-tert-butyl 4-(4-amino-5-(ethoxycarbonyl)-1H-pyrrol-3-yl)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H)-carboxylate 
• 222631-14-3 (3aS,4S,6R,6aR)-tert-butyl 4-(4-((E)-(benzamido(methylthio)methylene)amino)-5-(ethoxycarbonyl)-1H-pyrrol-3-yl)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H)-carboxylate 
• 222631-11-0 N-tert-butoxycarbonyl-7-O-tert-butyldimethylsilyl-2-cyano-1,2,3,6-tetradeoxy-1-N-(ethoxycarbonylmethylamino)-3,6-imino-4,5-O-isopropylidene-D-allo-hept-1-enitol 

Relevant articles and documents

ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES

Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.